D3S-001
Highest phase reached
Phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Small molecule
- Drug name
- D3S-001
- Molecular weight
- 679.67
- Structure (SMILES)
- C=C(F)C(=O)N1CCN(c2nc(OC[C@@]34CCCN3C[C@H](F)C4)nc3c2CO[C@H](c2c(F)c(N)cc(C)c2C(F)(F)F)C3)C[C@@H]1CC#N
- d3s 001
- D3s-001
- D3S-001
- elisrasib
- Elisrasib
- elisrasib [INN]
- ELISRASIB [USAN]
- elisrasib inn
- elisrasib usan
- CAS registry numbers
- 2914919-85-8
- ChEMBL ID
- CHEMBL5314913
- InChIKey
- JOLORSRKBHXPFT-PNGHJTAWSA-N
- PubChem compound IDs
- 167251905
- FDA ingredient codes (UNII)
- PFW9YLB86H
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- elisrasib
- Type
- Synthetic organic
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- KRAS
- Gene symbol
- KRAS
- Protein identifier
- P01116
- Median affinity
- 10.18
- Affinity units
- pKi
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 1
- Polar surface area
- 120.84
- Calculated partition coefficient (ALogP)
- 4.71
- Calculated partition coefficient (XLogP)
- 3.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 7
- Heavy atoms
- 48
- Molecular formula
- C32H35F6N7O3
- Monoisotopic mass
- 679.27055698
- Natural product
- No
Related records
Trials (3)
- A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Healthy Adult Participants
- A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
- A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation